Karen M. Lee

发表

Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

S. Sullivan, J. Mauskopf, F. Augustovski, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

Jing Jing Li, Braden J. Manns, Anthony Harris, 2009, JAMA.

Use of Evidence in Decision Models

Doug Coyle, Nicola J. Cooper, Karen M. Lee, 2010 .

Table 59, Results of Exploratory Analysis (Genotype 1 Treatment-Naive Non-cirrhotic Patients) With SOF8 + LDV8 and DCV12 + SOF12 Included (Assume Price of DCV12 + SOF12 = $43,000) — Analysis (h–i)

Karen Lee, Murray Krahn, William Wong, 2016 .

The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis

D. Coyle, Karen M. Lee, Douglas Coyle, 1998, PharmacoEconomics.

Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women

Peter Tugwell, Ann Cranney, Vivian Welch, 2012, PharmacoEconomics.

OP145 The Release Of The Fourth Edition Canadian Agency For Drugs And Technologies In Health (CADTH) Economic Guidelines – A Year In Review

D. Coyle, Karen M. Lee, 2018, International Journal of Technology Assessment in Health Care.

ComparativeHealthSystemsResearchamongKaiserPermanenteand OtherIntegratedDeliverySystems:ASystematicLiteratureReview

M. Horberg, Karen M. Lee, J. L. Maeda, 2014 .

Comparative health systems research among Kaiser Permanente and other integrated delivery systems: a systematic literature review.

M. Horberg, Karen M. Lee, J. L. Maeda, 2014, The Permanente journal.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

D. Coyle, G. Wells, K. Coyle, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Role of Models Within Economic Analysis

B. O'brien, D. Coyle, Karen M. Lee, 2012, PharmacoEconomics.

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation

M. Tonelli, B. Manns, S. Klarenbach, 2016 .

Cost Effectiveness of Epoetin-α to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery

A. Laupacis, D. Coyle, D. Fergusson, 2000, PharmacoEconomics.

Economic Analysis of Erythropoietin Use in Surgery

A. Laupacis, D. Coyle, D. Fergusson, 1997 .

Table 8, Therapy Cost

Sumeet Singh, Murray Krahn, William Wong, 2016 .

Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study

D. Coyle, K. Coyle, L. Mielniczuk, 2016, PharmacoEconomics.

Reimbursement‐Based Economics – What Is It and How Can We Use It to Inform Drug Policy Reform?

D. Coyle, M. Mamdani, Karen M. Lee, 2015, Headache.

Designing economic evaluations to facilitate optimal decisions: the need to avoid bias

D. Coyle, K. Coyle, Karen M. Lee, 2016, ClinicoEconomics and outcomes research : CEOR.

Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.

Joseph C Cappelleri, Rachael Fleurence, Neil Hawkins, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.

B. Levy, A. Saxena, Karen M. Lee, 2015, The oncologist.

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

Sumeet Singh, G. Wells, M. Krahn, 2017, CMAJ open.

Drugs for Chronic Hepatitis C Infection: Cost-Effectiveness Analysis

M. Krahn, Karen M. Lee, W. Wong, 2016 .

Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review

Karen M. Lee, J. Blouin, 2009 .

The role of models within economic analysis: focus on type 2 diabetes mellitus.

Bernie J O'Brien, B. O'brien, D. Coyle, 2002, PharmacoEconomics.

Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration

G. Wells, S. Kelly, D. So, 2019 .